Syndax Pharmaceuticals Inc Stock Price, News & Analysis

Syndax Pharmaceuticals, Inc. (SNDX) will release its third quarter 2021 financial results on November 15, after U.S. market close. A conference call and live audio webcast will occur at 4:30 p.m. ET on the same day to discuss these results and provide a business update. The details for accessing the call are provided, including dial-in numbers and a link for the webcast. Syndax is focused on innovative cancer therapies, with a pipeline that includes SNDX-5613, axatilimab, and entinostat.

Syndax Pharmaceuticals (Nasdaq: SNDX) announced that updated data for its cancer therapies, SNDX-5613 and axatilimab, will be presented at the 63rd ASH Annual Meeting from December 11-14, 2021. SNDX-5613, a selective oral menin inhibitor, showed a 44% composite complete response rate in patients with MLLr and NPM1c mutations. Axatilimab demonstrated a 66% overall response rate in chronic graft-versus-host disease patients. Both programs highlight Syndax's commitment to developing innovative cancer treatments.

Flare Therapeutics has expanded its leadership team with the appointments of Daphne Karydas as COO and CFO, and Michaela Bowden as SVP of Biology and Translation. Karydas, with over 20 years in biopharma, previously served as CFO for Syndax Pharmaceuticals (SNDX). Bowden, holding a PhD, brings extensive experience from Bristol Myers Squibb. The company aims to enhance its precision oncology pipeline by leveraging their expertise in developing small molecule medicines targeting transcription factors.

Syndax Pharmaceuticals and Incyte announced a global collaboration to develop axatilimab, an anti-CSF-1R monoclonal antibody, focusing on chronic graft-versus-host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). Syndax will receive $117 million upfront and $35 million in equity investment, along with potential milestone payments of up to $450 million. The companies will share profits in the U.S. 50:50, with Syndax receiving double-digit royalties internationally. Ongoing trials for axatilimab aim to provide innovative treatments for patients with severe conditions, with topline data expected in 2023.

Syndax Pharmaceuticals has expanded its Board of Directors to nine members by appointing Dr. Martin H. Huber, M.D., effective immediately. Dr. Huber brings over 20 years of experience in drug development, currently serving as President of R&D at Xilio Therapeutics. The company's leadership expressed confidence in Dr. Huber's expertise, highlighting its potential to enhance Syndax's innovative cancer therapy pipeline, including drug candidates like SNDX-5613 and axatilimab. This strategic appointment aims to strengthen the company's ability to serve underserved cancer patients.

Syndax Pharmaceuticals, a clinical stage biopharmaceutical company, announced its participation in three virtual investor conferences. The events include a fireside chat at the Morgan Stanley Global Healthcare Conference on September 9, 2021, a panel at the Citi BioPharma Virtual Conference on September 10, and another fireside chat at the Baird Global Healthcare Conference on September 14. Investors can access a live webcast of the first two events and find replays on the company's website. Syndax is developing innovative cancer therapies, including SNDX-5613 and axatilimab.

Syndax Pharmaceuticals (SNDX) reported Q2 2021 financial results, highlighting significant progress in their cancer therapy pipeline. As of June 30, 2021, the company had $253.1 million in cash and equivalents. Research and development expenses rose to $16.9 million, up from $10.9 million year-over-year. Syndax reported a net loss of $22.9 million, or $0.44 per share, compared to a loss of $17.1 million, or $0.42 per share, in Q2 2020. Looking ahead, the company expects R&D expenses to reach $25-$30 million in Q3.

Syndax Pharmaceuticals will release its second quarter 2021 financial results on August 9 after U.S. market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide a business update. The company is focused on developing cancer therapies, including SNDX-5613, axatilimab, and entinostat. Investors can access the live webcast and slides on the Syndax website.

Syndax Pharmaceuticals has announced that the FDA granted Fast Track Designation to its oral menin inhibitor, SNDX-5613, for treating relapsed or refractory acute leukemias with specific mutations. This designation aims to expedite the drug's development and review process, highlighting SNDX-5613's potential to improve patient outcomes in an area with high unmet medical need. Currently under evaluation in the AUGMENT-101 clinical trial, SNDX-5613 has shown preclinical promise with significant tumor growth inhibition.